Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
about
Molecular Profiling in Resectable Colorectal Liver Metastases: The Role of KRAS Mutation Status in Assessing Prognosis in the Preoperative SettingNew and emerging factors in tumorigenesis: an overviewTargeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicineHeat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panelAllele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutationOutcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practicePatient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer.KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma.Genomic and biological characterization of exon 4 KRAS mutations in human cancerKRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancerExpression of Abelson interactor 1 (Abi1) correlates with inflammation, KRAS mutation and adenomatous change during colonic carcinogenesis.Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations.Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors.KRAS mutation testing in metastatic colorectal cancerBevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.Biology of colorectal cancer.Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order.ITF-2B protein levels are correlated with favorable prognosis in patients with colorectal carcinomas.Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.Optimized Multiplex Detection of 7 KRAS Mutations by Taqman Allele-Specific qPCR.Probing spatial organization of DNA strands using enzyme-free hairpin assembly circuitsKRAS and VEGF gene 3'-UTR single nucleotide polymorphisms predicted susceptibility in colorectal cancer.Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon CancersEGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.The functional relevance of somatic synonymous mutations in melanoma and other cancers.Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy.Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer.Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer.Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports.
P2860
Q26749002-E1A30044-C2AF-4E9F-8706-6E094011D34BQ26801253-293167B1-F37B-40F5-A0ED-C8D7BE75B055Q26865436-726FD82B-38A8-4F17-9754-A946860AA26FQ27851677-4013A977-37E7-43CA-8518-CA384275D85DQ27851892-28FA8741-039C-47C5-8888-BF4E2B04A6CFQ28541288-89307576-F1FE-410B-AD7C-E9CA0835751AQ28730199-53B8992A-6557-48DB-8479-00F84032487FQ30314225-259BECD6-F26C-4C6E-B882-D0C49B4617A3Q33590020-3C314A9C-F960-4578-8BF4-9CD109A4CF30Q33759960-370AB39A-1D1A-4AD4-AFF5-E2F80A5CD555Q33947880-FA8F0BD0-D5C8-4B76-9BC2-CE4BFEA594B1Q34084873-40BA0534-059C-4A96-B485-4196092461D6Q34141770-D901C66F-5D12-4BB8-93E4-CDCFF7AE0055Q34145806-F199264C-DCFA-42D3-AEE5-F0E7D127E488Q34269163-394CC15D-765D-4E1D-BFAA-D725A4E1C427Q34342261-AD13C76C-E7DF-451E-8E0C-12FA07912CD7Q34532108-1E3677CF-9E41-4079-9A89-5EB66620E84FQ34598203-04CDA46E-5F85-4735-8EAA-6E33A5306133Q34607305-67259B1C-EDC1-4E3C-8463-A2C21387FE98Q34643960-771217FA-1A15-49EC-9009-4DAF7F7DCF3EQ34654266-81D3A473-6A62-4E1B-A03C-32E0BA9423ACQ34669618-CB398F86-8034-4590-A371-CD4595EB5991Q35067570-50709AD2-61AA-4885-BB49-091A5C614BAAQ35584550-2E3B8429-FF6A-4E99-85A6-613C00132496Q35782746-2239301C-AE01-47FA-9273-286D4617904FQ35993139-25BEEE45-7F71-45B1-A795-002FBE854431Q36086845-8DFFE9E0-9ABB-40AA-9DAE-3554E9D992F4Q36134534-6483FBE5-F141-4010-8DEC-A3CCF3AFF298Q36292989-70B3D3B4-C000-400B-B2B6-748BAF2AA3B2Q36318292-0456FDA1-C03C-4FA6-9529-9A14CBF759CAQ36393095-E6E38908-C278-4E5D-A57E-03916F0E84C4Q36416491-C5C70387-5DBC-423D-A991-E1DAEC973431Q36487348-049C5BFC-258D-45CE-94F7-279E0D934C8BQ36594155-8A44843D-E4F9-4764-B185-17F49459DFFDQ36805023-9984A27D-99AB-44E0-A3D9-A267211EDF19Q36997408-7A0E227D-3E76-40BE-8C68-453F77E48CA7Q37016996-2652BF7E-61D2-4F43-BBC1-17C20B655D27Q37031288-944E4C32-7CD1-412A-A52A-A74935D08A5DQ37317549-4C6CFB7D-DF97-4951-9987-86B9E9724927Q37878380-356761B1-CAEA-4E9E-AB55-C478E8E4C8D1
P2860
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Frequency and type of KRAS mut ...... metastatic colorectal cancer.
@en
Frequency and type of KRAS mut ...... metastatic colorectal cancer.
@nl
type
label
Frequency and type of KRAS mut ...... metastatic colorectal cancer.
@en
Frequency and type of KRAS mut ...... metastatic colorectal cancer.
@nl
prefLabel
Frequency and type of KRAS mut ...... metastatic colorectal cancer.
@en
Frequency and type of KRAS mut ...... metastatic colorectal cancer.
@nl
P2093
P1476
Frequency and type of KRAS mut ...... metastatic colorectal cancer.
@en
P2093
Andreas Jung
Evelyn Zeindl-Eberhart
Jens Neumann
Thomas Kirchner
P304
P356
10.1016/J.PRP.2009.07.010
P577
2009-08-12T00:00:00Z